Loading...
Loading...
IPSC| Name | Value |
|---|---|
| Revenues | 1.7M |
| Cost of Revenue | 2.2M |
| Gross Profit | -0.5M |
| Operating Expense | 33.8M |
| Operating I/L | -32.1M |
| Other Income/Expense | 2.0M |
| Interest Income | 2.6M |
| Pretax | -30.1M |
| Income Tax Expense | 1.2M |
| Net Income/Loss | -31.3M |
Century Therapeutics, Inc. is a biotechnology company specializing in allogeneic cell therapies for solid tumor and hematological malignancies. Their lead product, CNTY-101, is an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. The company also develops other CAR-iNK and CAR-iT candidates targeting various cancer types, including recurrent glioblastoma, B-cell lymphoma, acute myeloid leukemia, and multiple myeloma.
